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Six novel ruthenium(II)- and osmium(II)-arene complexes with indoloquinoline modiﬁed ligands con-
taining methyl and halo substituents in position 8 of the molecule backbone have been synthesised
and comprehensively characterised by spectroscopic methods (1H, 13C NMR, UV–Vis), ESI mass spectro-
metry and X-ray crystallography. Binding of indoloquinolines to a metal-arene scaffold makes the
products soluble enough in biological media to allow for assaying their antiproliferative activity. The
complexes were tested in three human cancer cell lines, namely A549 (non-small cell lung cancer),
SW480 (colon carcinoma) and CH1 (ovarian carcinoma), yielding IC50 values in the 106–107 M concen-
tration range after continuous exposure for 96 h. Compounds with halo substituents in position 8 are
more effective cytotoxic agents in vitro than the previously reported species halogenated in position 2
of the indoloquinoline backbone. High antiproliferative activity of both series of substances may be
due at least in part to their potential to act as DNA intercalators.
 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
The ﬁght against cancer has made considerable progress by the
introduction of targeted therapies in recent years. This treatment
modality takes advantage of certain features of malignant tumours
to selectively inhibit their growth, ideally associated with low side
effects for patients. The numerous concepts that are currently
being explored to achieve tumour targeting in bioinorganic medic-
inal chemistry include ‘activation by reduction’ in hypoxic media,
as well as ‘activation by ring opening’ in the solid tumour environ-
ment with lowered pH value [1–4]. Activation by reduction is be-
lieved to be the critical step in converting a prodrug into its
active form [5]. Well-known examples supporting this hypothesis
are satraplatin, a PtIV compound that reached a clinical phase III
study [6], NAMI-A [7], as well as KP1019 [8], the ﬁrst ruthe-
nium(III) coordination compounds in clinical studies. Another
way to gain selectivity for malignant cells over healthy tissue is
targeting enzymes or receptors that are overexpressed in certain
tumour types, e.g. thioredoxin reductase [9], ribonucleotide reduc-
tase [10,11], DNA topoisomerase [12] or glutathione S-transferase
[13]. Another example are ferrocifen derivatives [14], which are
based on hydroxytamoxifen, an oestrogen receptor antagonist usedY-NC-ND license. 
x: +43 1 4277 52630.
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ion).in hormone-positive breast cancer therapy [15]. In ferrocifen, one
of the phenyl rings is replaced by a ferrocenyl unit, combining
the hormone-antagonistic ligand with a metal–organic redox ac-
tive moiety. Similar attempts combining the beneﬁts of organome-
tallic core with biologically active ligands were undertaken with
indolobenzazepines, also referred to as paullones. The paullones
were originally predicted to possess cyclin dependent kinase
(CDK)-inhibitory properties by a COMPARE analysis [16]. CDKs to-
gether with their corresponding cyclins act as cell cycle triggers,
controlling cell division [17]. By interference with this highly
balanced regulatory system, cell proliferation can be controlled.
In vitro models conﬁrmed the CDK-inhibitory properties of the
paullones [18], and up to date a broad range of paullone derivatives
has been evaluated for biological activity [19,20]. For some paull-
ones, other intracellular targets such as glycogen synthase kinase
3b (GSK3b) and mitochondrial malate dehydrogenase (mMDH)
could be identiﬁed [21].
Indoloquinolines also attracted interest during the last few
years [22–26] due to the development of convenient preparation
routes [27]. In contrast to paullones with a folded seven-mem-
bered azepine ring, indoloquinolines are ﬂat heteroaromatic ring
systems, in which the paullone azepine ring was replaced by a
six-membered pyridine ring. We anticipated that this transforma-
tion will alter signiﬁcantly the physico-chemical and biological
properties compared to the reference (paullone) compounds.
In order to overcome their limited solubility in biocompatible
media, paullones were complexed to metal ions. Ga(III) [28], Ru(II)
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Ru(II)- and Os(II)-arene complexes of modiﬁed paullone ligands
[31–33] are well-documented in the literature. Interestingly, CDK
inhibition by metal-based paullones does not necessarily parallel
their in vitro antiproliferative activity, making other intracellular
targets likely to be involved in their mechanism of action [34].
Novel SAR studies showed that some ruthenium- and osmium-
arene complexes of indoloquinolines are by a factor of 10 more ac-
tive than corresponding paullone complexes in human cancer cell
lines. It is worth noting, however, that the indoloquinoline-based
complexes with a bidentate ethylenediamine binding site are less
stable than their paullone counterparts, dissociating in aqueous
media with release of the ligand [34]. Remarkably, other ethylene-
diamine based ruthenium-arene complexes do not show propen-
sity for dissociation under similar conditions [35–37]. To increase
the thermodynamic stability and kinetic inertness of the
complexes, sp2-hybridised N-donor atoms were introduced by
condensation of an indoloquinoline azine with 2-formyl- or 2-ace-
tylpyridine [38]. This modiﬁcation led to complexes with increased
stability in biocompatible media, while retaining the in vitro anti-
proliferative activity. Further studies on modiﬁed indoloquinolines
containing different substituents in position 2 of the molecular
backbone showed that electron-withdrawing substituents are
unfavourable for cytotoxicity, whereas an electron-donating
methyl group has no inﬂuence on antiproliferative activity. The
effect of substituents in position 8 of the indoloquinoline backbone
was studied on copper(II) complexeswhichwere found highly cyto-
toxic with IC50 values in the nanomolar concentration range [39].
Synthesis of those ligands is depicted in Scheme 1.
Hereinwe report on the synthesis of six novel ruthenium-andos-
mium-arene complexes with indoloquinoline-based ligands (1a,b–
3a,b) containing substituents with different electronic properties
inposition8of the indoloquinoline backbone (Scheme2). Their anti-
proliferative activity in three human cancer cell lines, namely A549
(non-small cell lung cancer), SW480 (colon carcinoma) and CH1
(ovarian carcinoma) has been studied and compared to that of
chemically related complexes (4a,b–6a,b and others).2. Experimental
2.1. Chemicals
Ethanol and THF were dried using standard procedures. a-Ter-
pinene, 2-amino-5-chlorobenzonitrile were purchased from Acros
Fisher, ruthenium trichloride and osmium tetroxide from JohnsonScheme 1. Synthesis of the indoloquinoline modiﬁed ligands [38,39]. Reagents and cond
Ar, reﬂux, 26 h; (iv) N2H4H2O, Ar, 100 C, 24 h; (v) 2-acetylpyridine, EtOH, Ar, 65 C, 18Matthey, KBr from Merck, while 2-acetylpyridine, hydrazine dihy-
drochloride, hydrazine hydrate, phosphorus oxychloride, isatin,
glacial acetic acid, borane in THF, 2-aminobenzonitrile, 2-amino-
5-methylbenzonitrile, sodium perborate tetrahydrate were from
Sigma–Aldrich. All these chemicals were used as received.2.2. Synthesis
The ligands HL13 were synthesized by following the literature
protocols [38,39]. Ruthenium- and osmium-arene starting com-
pounds [M(p-cymene)(Cl)(l-Cl)]2, where M = RuII and OsII, were
prepared as described previously [40,41]. For preparation of
[Os(p-cymene)(Cl)(l-Cl)]2 OsO4 was reduced ﬁrst to H2[OsCl6] by
N2H42HCl in conc. HCl [42], and then reacted with a-terpinene.
General procedure A for the complexation of HL13 to the
metal-arene scaffold: The corresponding ligand HL13 in a Schlenk
tube was ﬂushed with argon and suspended in dry ethanol. The
corresponding metal-arene dimer was dissolved in chloroform
and added to the ethanolic ligand suspension. The reaction mixture
was stirred at room temperature under argon atmosphere (in the
case of the Os complexes, light protection was also applied). The
reaction mixture was ﬁltered through a GF3 ﬁlter paper, and
slowly added to diethyl ether previously dried over sodium sulfate.
The precipitate formed was separated by ﬁltration and dried
in vacuo at 50 C.2.2.1. [Ru(p-cymene)(HL1)Cl]Cl, 1a
General procedure A: N-(8-Methyl-5,11-dihydroindolo [3,2-c]—
quinolin-6-ylidene)-N’-(1-pyridin-2-yl-ethylidene)azine (HL1,
120 mg, 0.33 mmol), bis((g6-p-cymene)(chlorido)(l-chlorido)
ruthenium(II)) (101 mg, 0.16 mmol), EtOH abs. (4 mL), CHCl3
(0.3 mL), diethyl ether dried over Na2SO4 (100 mL), stirring for
22.5 h. To remove traces of the unreacted ruthenium dimer the red
precipitate was dissolved in a minimal amount of EtOH and ﬁltered
through aGF3ﬁlter paper. After addition of CHCl3 (1 mL), the ﬁltrate
was added dropwise to diethyl ether previously dried over Na2SO4
(100 mL). The resulting precipitate was ﬁltered off and dried in va-
cuo at 50 C. Yield 154 mg, 69%.Anal.Calc. for C33H33Cl2N5Ru1.5H2O
(Mr 698.65): C, 56.73; H, 5.19; N, 10.02. Found: C, 56.64; H, 5.01; N,
9.94%. ESI-MS (methanol), positive:m/z 636 [MCl]+.
1H NMR (500 MHz, DMSO-d6): 12.99 (s, 1H, H11), 10.36 (s, 1H,
H5), 9.60 (d, 1H, 3J = 6 Hz, H17), 8.36 (d, 1H, 3J = 8 Hz, H1), 8.31–
8.26 (m, 1H, H19), 8.23–8.19 (m, 2H, H7 + H20), 7.83–7.79 (m, 1H,
H18), 7.63 (d, 1H, 3J = 8.3 Hz, H10), 7.61–7.57 (m, 2H, H3 + H4),
7.42 (ddd, 1H, 3J = 8 Hz, 3J = 6 Hz, 4J = 2 Hz, H2), 7.31 (dd, 1H,itions: (i) BH3THF, THF, Ar, r.t., 24–72 h; (ii) glacial HOAc, reﬂux, 3–4 h; (iii) POCl3,
h.
HN
H
N N
N
N
M
Cl
Cl
1a: R1 = CH3, R2 = H, M = RuII
1b: R1 = CH3, R2 = H, M = OsII
2a: R1 = Cl, R2 = H, M = RuII
2b: R1 = Cl, R2 = H, M = OsII
3a: R1 = Br, R2 = H, M = RuII
3b: R1 = Br, R2 = H, M = OsII
R1
4a: R1 = H, R2 = CH3, M = RuII
4b: R1 = H, R2 = CH3, M = OsII
5a: R1 = H, R2 = Cl, M = RuII
5b: R1 = H, R2 = Cl, M = OsII
6a: R1 = H, R2 = Br, M = RuII
6b: R1 = H, R2 = Br, M = OsIIR2 2
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Scheme 2. Ruthenium- and osmium-arene complexes with substituted indoloquinoline ligands. (See Ref. [38] for details about 4a,b–6a,b.)
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3J = 6 Hz, Hcy2), 5.71 (d, 1H, 3J = 6 Hz, Hcy1’), 5.30 (d, 1H, 3J = 6 Hz,
Hcy2’), 2.78–2.72 (m, 1H, Hcy3), 2.71 (s, 3H, H21), 2.54 (s, 3H, H8a),
2.13 (s, 3H, Hcy5), 1.08 (d, 3H, 3J = 7 Hz, Hcy4’), 1.04 (d, 3H,
3J = 7 Hz, Hcy4) ppm.
13C NMR (125 MHz, DMSO-d6): 166.18 (Cq, C14), 156.36 (CH,
C17), 155.32 (Cq, C15), 147.54 (Cq, C6), 140.28 (CH, C19), 139.42 (Cq,
C11a), 137.20 (Cq, C10a), 136.69 (Cq, C4a), 130.77 (Cq, C8), 130.21
(CH, C3), 127.34 (CH, C18), 126.59 (CH, C20), 126.54 (CH, C9), 124.15
(Cq, C6b), 123.41 (CH, C2), 123.09 (CH, C1), 121.91 (CH, C7), 117.12
(CH, C4), 113.57 (Cq, C11b), 112.23 (CH, C10), 104.17 (Cq, Ccy1a),
103.78 (Cq, C6a), 103.35 (Cq, Ccy2a), 87.66 (CH, Ccy1’), 86.45 (CH,
Ccy1), 86.14 (CH, Ccy2), 84.70 (CH, Ccy2’), 31.05 (CH, Ccy3), 22.25 (CH,
Ccy4), 22.04 (CH, C8a), 21.78 (CH, Ccy4’), 18.94 (CH, Ccy5), 15.99 (CH,
C21) ppm.2.2.2. [Os(p-cymene)(HL1)Cl]Cl, 1b
General procedure A: N-(8-Methyl-5,11-dihydroindolo[3,2-
c]quinolin-6-ylidene)-N’-(1-pyridin-2-yl-ethylidene)azine (HL1,
150 mg, 0.41 mmol), bis((g6-p-cymene)(chlorido)(l-chlori-
do)osmium(II)) (167 mg, 0.22 mmol), EtOH abs. (4 mL), CHCl3
(1.1 mL), diethyl ether dried over Na2SO4 (100 mL), stirring for
18 h. Yield 207 mg, 66%. Anal. Calc. for C33H33Cl2N5Os1.5H2O (Mr
787.81): C, 50.31; H, 4.61; N, 8.89. Found: C, 50.40; H, 4.45; N,
8.87%. ESI-MS (methanol), positive: m/z 726 [MCl]+.
1H NMR (500 MHz, DMSO-d6): 13.03 (s, 1H, H11), 9.96 (s, 1H,
H5), 9.54 (d, 1H, 3J = 6 Hz, H17), 8.36 (d, 1H, 3J = 8 Hz, H1), 8.32 (d,
1H, 3J = 8 Hz, H20), 8.29–8.25 (m, 1H, H19), 8.15 (s, 1H, H7), 7.82–
7.78 (m, 1H, H18), 7.63 (d, 1H, 3J = 8 Hz, H10), 7.60–7.55 (m, 1H,
H3), 7.45 (d, 1H, 3J = 8 Hz, H4), 7.42–7.38 (m, 1H, H2), 7.30 (dd,
1H, 3J = 8 Hz, 4J = 1 Hz, H9), 6.32 (d, 1H, 3J = 6 Hz, Hcy1), 6.02 (d,
1H, 3J = 6 Hz, Hcy2), 5.97 (d, 1H, 3J = 6 Hz, Hcy1‘), 5.43 (d, 1H,
3J = 6 Hz, Hcy2‘), 2.78 (s, 3H, H21), 2.69–2.60 (m, 1H, Hcy3), 2.53 (s,
3H, H8a), 2.18 (s, 3H, Hcy5), 1.03 (d, 3H, 3J = 7 Hz, Hcy4‘), 1.00 (d,
3H, 3J = 7 Hz, Hcy4) ppm.
13C NMR (125 MHz, DMSO-d6): 167.18 (Cq, C14), 156.30 (Cq, C15),
156.28 (CH, C17), 147.66 (Cq, C6), 140.40 (CH, C19), 139.35 (Cq, C11a),
137.17 (Cq, C10a), 136.47 (Cq, C4a), 130.76 (Cq, C8), 130.20 (CH, C3),
128.21 (CH, C18), 126.74 (CH, C20), 126.51 (CH, C9), 124.11 (Cq,
C6b), 123.38 (CH, C2), 123.13 (CH, C1), 121.83 (CH, C7), 117.04 (CH,
C4), 113.50 (Cq, C11b), 112.24 (CH, C10), 103.42 (Cq, C6a), 96.47 (Cq,
Ccy2a), 95.29 (Cq, Ccy1a), 79.44 (CH, Ccy1’), 78.23 (CH, Ccy1), 76.70
(CH, Ccy2), 75.16 (CH, Ccy2’), 31.21 (CH, Ccy3), 22.55 (CH, Ccy4), 22.02
(CH, C8a), 21.89 (CH, Ccy4’), 18.84 (CH, Ccy5), 15.74 (CH, C21) ppm.2.2.3. [Ru(p-cymene)(HL2)Cl]Cl, 2a
General procedure A: N-(8-Chloro-11H-indolo[3,2-c]quinolin-
6-yl)-N’-(1-pyridine-2-yl-ethylidene)azine (HL2, 100 mg, 0.26
mmol) and bis((g6-p-cymene)(chlorido)(l-chlorido)ruthenium(II))
(80 mg, 0.13 mmol). Yield 103 mg, 58%. Anal. Calc. for
C32H30Cl3N5Ru1.5H2O (Mr 719.07): C, 53.45; H, 4.63; N, 9.74.Found: C, 53.50; H, 4.41; N, 9.69%. ESI-MS (methanol), positive:
m/z 656 [MCl]+.
1H NMR (500 MHz, DMSO-d6): 13.42 (s, 1H, H11), 10.42 (s, 1H,
H5), 9.61 (d, 1H, 3J = 5 Hz, H17), 8.40 (d, 1H, 3J = 8 Hz, H1), 8.34 (d,
1H, 4J = 2 Hz, H7), 8.32–8.27 (m, 1H, H19), 8.22 (d, 1H, 3J = 8 Hz,
H20), 7.84–7.79 (m, 1H, H18), 7.77 (d, 1H, 3J = 9 Hz, H10), 7.65–
7.61 (m, 1H, H3), 7.59 (d, 1H, 3J = 8 Hz, H4), 7.49 (dd, 1H,
3J = 9 Hz, 4J = 2 Hz, H9), 7.46–7.41 (m, 1H, H2), 6.06 (d, 1H,
3J = 6 Hz, Hcy1), 5.82 (d, 1H, 3J = 6 Hz, Hcy2), 5.76 (d, 1H, 3J = 6 Hz,
Hcy1‘), 5.33 (d, 1H, 3J = 6 Hz, Hcy2‘), 2.77–2.67 (m, 1H, Hcy3 + s, 3H,
H21), 2.12 (s, 3H, Hcy5), 1.07 (d, 3H, 3J = 7 Hz, Hcy4‘), 1.04 (d, 3H,
3J = 7 Hz, Hcy4) ppm.
13C NMR (125 MHz, DMSO-d6): 166.75 (Cq, C14), 156.39 (CH,
C17), 155.18 (Cq, C15), 147.23 (Cq, C6), 140.58 (Cq, C11a), 140.33
(CH, C19), 137.45 (Cq, C10a), 137.03 (Cq, C4a), 130.79 (CH, C3),
127.51 (CH, C18), 126.76 (CH, C20), 126.31 (Cq, C8), 125.02 (Cq,
C6b), 124.95 (CH, C9), 123.55 (CH, C2), 123.42 (CH, C1), 121.13 (CH,
C7), 117.19 (CH, C4), 114.19 (CH, C10), 113.28 (Cq, C11b), 104.17
(Cq, Ccy1a), 103.59 (Cq, C6a), 103.37 (Cq, Ccy2a), 87.45 (CH, Ccy1’),
86.69 (CH, Ccy1), 86.11 (CH, Ccy2), 84.81 (CH, Ccy2’), 31.06 (CH, Ccy3),
22.33 (CH, Ccy4), 21.70 (CH, Ccy4’), 18.95 (CH, Ccy5), 16.02 (CH, C21)
ppm.2.2.4. [Os(p-cymene)(L2)Cl]Cl, 2b
N-(8-Chloro-11H-indolo[3,2-c]quinolin-6-yl)-N’-(1-pyridine-2-
yl-ethylidene)azine (150 mg, 0.19 mmol) and bis((g6-p-
cymene)(chlorido)(l-chlorido)osmium(II)) in a 25 mL Schlenk tube
were suspendend in dry ethanol (3 mL) under Ar. The mixture was
stirred for 24 h at room temperature. The precipitate formed was
collected under suction, washed with small amounts of ethanol
and dried in vacuo at 50 C. Yield 268 mg, 88%. Anal. Calc. for
C32H30Cl3N5Os2.25H2O (Mr 821.74): C, 46.77; H, 4.23; N, 8.52.
Found: C, 46.58; H, 3.83; N, 8.40%. ESI-MS (methanol), positive:
m/z 746 [MCl]+.
1H NMR (500 MHz, DMSO-d6): 13.36 (s, 1H, H11), 10.03 (s, 1H,
H5), 9.54 (d, 1H, 3J = 6 Hz, H17), 8.37 (d, 1H, 3J = 8 Hz, H1), 8.34 (d,
1H, 3J = 8 Hz, H20), 8.30 (d, 1H, 4J = 2 Hz, H7), 8.29–8.25 (m, 1H,
H19), 7.83–7.79 (m, 1H, H18), 7.76 (d, 1H, 3J = 9 Hz, H10), 7.63–
7.59 (m, 1H, H3), 7.49 (dd, 1H, 3J = 9 Hz, 4J = 2 Hz, H9), 7.46 (d,
1H, 3J = 8 Hz, H4), 7.44–7.40 (m, 1H, H2), 6.34 (d, 1H, 3J = 6 Hz,
Hcy1), 6.04–6.01 (m, 2H, Hcy1‘ + Hcy2), 5.47 (d, 1H, 3J = 6 Hz, Hcy2‘),
2.78 (s, 3H, H21), 2.67–2.59 (m, 1H, Hcy3), 2.18 (s, 3H, Hcy5), 1.02
(d, 3H, 3J = 7 Hz, Hcy4‘), 1.00 (d, 3H, 3J = 7 Hz, Hcy4) ppm.
13C NMR (125 MHz, DMSO-d6): 167.77 (Cq, C14), 156.29 (CH,
C17), 156.17 (Cq, C15), 147.35 (Cq, C6), 140.51 (Cq, C11a), 140.44
(CH, C19), 137.40 (Cq, C10a), 136.83 (Cq, C4a), 130.79 (CH, C3),
128.38 (CH, C18), 126.92 (CH, C20), 126.32 (Cq, C8), 125.00 (Cq, C6b),
124.95 (CH, C9), 123.54 (CH, C2), 123.37 (CH, C1), 121.07 (CH, C7),
117.14 (CH, C4), 114.19 (CH, C10), 113.18 (Cq, C11b), 103.28 (Cq,
C6a), 96.47 (Cq, Ccy2a), 95.34 (Cq, Ccy1a),79.26 (CH, Ccy1’), 78.46 (CH,
Ccy1), 76.71 (CH, Ccy2), 75.31 (CH, Ccy2’), 31.23 (CH, Ccy3), 22.62 (CH,
Ccy4), 21.82 (CH, Ccy4’), 18.85 (CH, Ccy5), 15.77 (CH, C21) ppm.
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General procedure A: N-(8-Bromo-11H-indolo[3,2-c]quinolin-
6-yl)-N’-(1-pyridine-2-yl-ethylidene)azine (120 mg, 0.28 mmol),
bis((g6-p-cymene)(chlorido)(l-chlorido)ruthenium(II)) (81 mg,
0.13 mmol), ethanol abs. (3 mL), CHCl3 (0.5 mL), diethyl ether dried
over Na2SO4 (180 mL), stirring for 23 h. Yield 124 mg (61%). Anal.
Calc. for C32H30BrCl2N5Ru1.5H2O (Mr 763.52): C, 50.34; H, 4.36;
N, 9.17. Found: C, 50.36; H, 3.97; N, 9.02%. ESI-MS (methanol), po-
sitive: m/z 702 [MCl]+.
1H NMR (500 MHz, DMSO-d6): 13.38 (s, 1H, H11), 10.41 (s, 1H,
H5), 9.61 (d, 1H, 3J = 5 Hz, H17), 8.50 (br s, 1H, H7), 8.38 (d, 1H,
3J = 8 Hz, H1), 8.32–8.26 (m, 1H, H19), 8.22 (d, 1H, 3J = 8 Hz, H20),
7.84–7.79 (m, 1H, H18), 7.72 (d, 1H, 3J = 9 Hz, H10), 7.66–7.57 (m,
3H, H3 + H4 + H9), 7.46–7.41 (m, 1H, H2), 6.05 (d, 1H, 3J = 6 Hz,
Hcy1), 5.83 (d, 1H, 3J = 6 Hz, Hcy2), 5.75 (d, 1H, 3J = 6 Hz, Hcy1‘),
5.34 (d, 1H, 3J = 6 Hz, Hcy2‘), 2.77–2.66 (m, 1H, Hcy3 + s, 3H, H21),
2.13 (s, 3H, Hcy5), 1.07 (d, 3H, 3J = 7 Hz, Hcy4‘), 1.04 (d, 3H,
3J = 7 Hz, Hcy4) ppm.
13C NMR (125 MHz, DMSO-d6): 166.78 (Cq, C14), 156.38 (CH,
C17), 155.18 (Cq, C15), 147.20 (Cq, C6), 140.39 (Cq, C11a), 140.32
(CH, C19), 137.71 (Cq, C10a), 137.04 (Cq, C4a), 130.81 (CH, C3),
127.52 (2 CH, C9 + C18), 126.77 (CH, C20), 125.64 (Cq, C6b), 124.17
(CH, C7), 123.56 (CH, C2), 123.39 (CH, C1), 117.20 (CH, C4), 114.61
(CH, C10), 114.27 (Cq, C8), 113.23 (Cq, C11b), 104.19 (Cq, Ccy1a),
103.47 (Cq, C6a), 103.37 (Cq, Ccy2a), 87.57 (CH, Ccy1’), 86.55 (CH,
Ccy1), 86.11 (CH, Ccy2), 84.82 (CH, Ccy2’), 31.06 (CH, Ccy3), 22.28 (CH,
Ccy4), 21.75 (CH, Ccy4’), 18.94 (CH, Ccy5), 16.02 (CH, C21) ppm.2.2.6. [Os(p-cymene)(L3)Cl]Cl, 3b
General procedure A: N-(8-Bromo-11H-indolo[3,2-c]quinolin-
6-yl)-N’-(1-pyridine-2-yl-ethylidene)azine (150 mg, 0.35 mmol),
bis((g6-p-cymene)(chlorido)(l-chlorido)osmium(II)) (137 mg,
0.17 mmol), ethanol abs. (3 mL), CHCl3 (0.5 mL), diethyl ether dried
over Na2SO4 (250 mL), stirring for 23 h. The precipitate was dis-
solved in ethanol (70 mL) and solution ﬁltered. The solvent was re-
moved under reduced pressure to ca. 5 mL and chloroform (1 mL)
was added. Then the mixture was added dropwise to diethyl ether
(300 mL) previously dried over Na2SO4, and the precipitate formed
was collected under suction in vacuo at 50 C. Further puriﬁcation
was achieved by crystallisation: dissolution of crude product
(100 mg) in ethanol (100 mL), evaporation of the solvent to
40 mL and slow diffusion of diethyl ether into the solution (under
Ar atmosphere). Yield: 71 mg (71%, based on 100 mg raw product
taken for the recrystallisation, overall yield 25%). Anal. Calc. for
C32H30BrCl2N5Os0.75H2O (Mr 839.17): C, 45.80; H, 3.78; N, 8.35.
Found: C, 45.48; H, 3.39; N, 8.28%. ESI-MS (methanol), positive:
m/z 790 [MCl]+.
1H NMR (500 MHz, DMSO-d6): 13.26 (s, 1H, H11), 10.02 (s, 1H,
H5), 9.53 (d, 1H, 3J = 6 Hz, H17), 8.46 (d, 1H, 4J = 2 Hz, H7), 8.36–
8.32 (m, 2H, H1 + H20), 8.30–8.25 (m, 1H, H19), 7.83–7.79 (m, 1H,
H18), 7.71 (d, 1H, 3J = 9 Hz, H10), 7.64–7.59 (m, 2H, H3 + H9), 7.46
(d, 1H, 3J = 8 Hz, H4), 7.45–7.40 (m, 1H, H2), 6.34 (d, 1H, 3J = 6 Hz,
Hcy1), 6.04 (d, 1H, 3J = 6 Hz, Hcy2), 6.01 (d, 1H, 3J = 6 Hz, Hcy1‘),
5.48 (d, 1H, 3J = 6 Hz, Hcy2‘), 2.78 (s, 3H, H21), 2.68–2.61 (m, 1H,
Hcy3), 2.19 (s, 3H, Hcy5), 1.04 (d, 3H, 3J = 7 Hz, Hcy4‘), 1.01 (d, 3H,
3J = 7 Hz, Hcy4) ppm.
13C NMR (125 MHz, DMSO-d6): 167.81 (Cq, C14), 156.28 (CH,
C17), 156.18 (Cq, C15), 147.31 (Cq, C6), 140.44 (CH, C19), 140.32 (Cq,
C11a), 137.66 (Cq, C10a), 136.85 (Cq, C4a), 130.81 (CH, C3), 128.38
(CH, C18), 127.53 (CH, C9), 126.93 (CH, C20), 125.63 (Cq, C6b),
124.12 (CH, C7), 123.55 (CH, C2), 123.31 (CH, C1), 117.17 (CH, C4),
114.60 (CH, C10), 114.29 (Cq, C8), 113.14 (Cq, C11b), 103.18 (Cq,
C6a), 96.49 (Cq, Ccy2a), 95.36 (Cq, Ccy1a), 79.42 (CH, Ccy1’), 78.32 (CH,
Ccy1), 76.73 (CH, Ccy2), 75.30 (CH, Ccy2’), 31.23 (CH, Ccy3), 22.57 (CH,
Ccy4), 21.88 (CH, Ccy4’), 18.84 (CH, Ccy5), 15.80 (CH, C21) ppm.2.3. Characterisation in solution
One-dimensional 1H and 13C NMR and two-dimensional 1H–1H
COSY, 1H–1H TOCSY, 1H–1H ROESY or 1H–1H NOESY, 1H–13C HSQC
and 1H–13C HMBC NMR spectra were recorded on two Bruker
Avance III spectrometers at 500.32 or 500.10 (1H), and 125.82 or
125.76 (13C) MHz, respectively, by using as a solvent DMSO-d6 or
CD3OD at room temperature and standard pulse programs. 1H
and 13C shifts are quoted relative to the solvent residual signals.
For the atom numbering scheme used for the NMR assignments,
see Chart S1. UV–Vis spectra were recorded with a Perkin Elmer
Lambda 650 spectrophotometer equipped with a six cell changer
and a Peltier element for temperature control or an Agilent 8453
spectrophotometer. Electrospray ionisation mass spectrometry
(ESI-MS) was carried out with a Bruker Esquire 3000 instrument;
the samples were dissolved in methanol. All elemental analyses
were performed at the Microanalytical Laboratory of the University
of Vienna with a Perkin Elmer 2400 CHN Elemental Analyzer. Ana-
lytical HPLC analysis was performed on a Dionex Summit system
controlled by DIONEX Chromelion 6.60 software. The experimental
conditions were as follows: a reversed phase silica-based C18 gel
as stationary phase (Zorbax SB-Aq, 4.6  250 mm, 5 lm pore size),
acetonitrile/15 mM aqueous formic acid as mobile phase with gra-
dient elution (5–80% acetonitrile), ﬂow rate 1.00 mL/min, concen-
tration of the investigated complexes: 0.1 mM; 30 lL as injection
volume; 25 C as column temperature; UV–Vis detection set at
225, 254, 280 and 300 nm.2.4. Crystallographic structure determination
X-ray diffraction measurements were performed on a Bruker X8
APEXII CCD diffractometer. Single crystals were positioned at 35,
35, 40, 35, 35 and 40 mm from the detector, and 890, 1086, 1292,
1615, 1278 and 1832 frames were measured, each for 60, 60, 50,
80, 30 and 30 s over 1 scan width for HL1, HL4CH3OH,
HL52C2H5OH 1b1.38H2O0.25(C2H5)2O, 3aCH3OH and
3b0.75H2O, respectively. The data were processed using SAINT soft-
ware [43]. Crystal data, data collection parameters, and structure
reﬁnement details are given in Table 1. The structures were solved
by direct methods and reﬁned by full-matrix least-squares tech-
niques. Non-H atoms were reﬁned with anisotropic displacement
parameters. H atoms were inserted in calculated positions and re-
ﬁned with a riding model. The following computer programs and
hardware were used: structure solution, SHELXS-97 and reﬁnement,
SHELXL-97 [44]; molecular diagrams, ORTEP [45] computer, Intel
CoreDuo.2.5. Cell lines and cell culture conditions
For cytotoxicity determination, three different cell lines were
used: A549, a human non-small cell lung cancer cell line, and
SW480, a human colon carcinoma cell line (both kindly provided
by Brigitte Marian, Institute of Cancer Research, Department of
Medicine I, Medical University of Vienna, Austria) as well as CH1,
a human ovarian carcinoma cell line (kindly provided by Lloyd R.
Kelland, CRC Centre for Cancer Therapeutics, Institute of Cancer Re-
search, Sutton, UK). Cells were grown as adherent monolayer cul-
tures in 75 cm2 culture ﬂasks (Iwaki/Asahi Technoglass) in
Minimal Essential Medium supplemented with 10% heat-inacti-
vated fetal bovine serum, 1 mM sodium pyruvate, 1% non essential
amino acids (from 100 ready-to-use stock) and 4 mM L-gluta-
mine but without antibiotics at 37 C under a moist atmosphere
containing 5% CO2 and 95% air. All cell culture media and reagents
were purchased from Sigma–Aldrich.
Table 1
Crystal data and details of data collection for HL1, HL4CH3OH, HL52C2H5OH, 1b1.38H2O0.25(C2H5)2O, 3aCH3OH and 3b0.75H2O.
Complex HL1 HL4CH3OH HL52C2H5OH 1b1.38H2O0.25(C2H5)2O 3aCH3OH 3b0.75H2O
Empirical formula C23H19N5 C24H23N5O C26H28ClN5O2 C34H38.25Cl2N5O1.63Os C33H34BrCl2N5ORu C32H31.5BrCl2N5O0.75Os
Forward 365.43 397.47 477.98 804.05 768.53 839.13
Space group P21/n P21/n P21/n P1 P1 P1
Unit cell dimensions
a (Å) 17.0279(16) 11.4565(7) 7.4390(6) 11.2980(9) 9.3254(5) 12.3508(4)
b (Å) 11.1855(11) 13.1693(7) 15.6393(14) 14.4940(12) 13.5216(8) 13.3564(5)
c (Å) 12.0305(11) 13.3620(8) 21.2178(18) 21.3506(18) 13.5306(8) 20.5840(8)
a () 99.901(5) 67.646(4) 98.018(2)
b () 129.439(4) 95.346(3) 99.794(5) 92.072(4) 89.989(4) 95.312(2)
c () 98.838(5) 85.886(3) 112.859(3)
V (Å3) 1769.6(3) 2007.2(2) 2432.5(4) 3396.2(5) 1573.17(16) 3057.97(19)
Z 4 4 4 4 2 4
k (Å) 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073
qcalcd. (g cm3) 1.372 1.315 1.305 1.573 1.622 1.823
Crystal size (mm3) 0.17  0.15  0.14 0.08  0.06  0.03 0.20  0.13  0.03 0.25  0.15  0.09 0.30  0.20  0.10 0.15  0.12  0.04
T (K) 100(2) 100(2) 100(2) 100(2) 100(2) 150(2)
l (mm1) 0.085 0.084 0.190 3.948 1.974 5.686
R1
a 0.0551 0.0527 0.0465 0.0386 0.0368 0.0208
wR2
b 0.1610 0.1427 0.1284 0.0988 0.0969 0.0506
Goodness-of-ﬁt (GOF)c 1.004 1.029 1.017 1.057 1.036 1.018
a R1 =R||Fo|  |Fc||/R|Fo|.
b wR2 = {R[w(Fo2  Fc2)2]/R[w(Fo2)2]}1/2.
c GOF = {R[w(Fo2  Fc2)2]/(n  p)}1/2, where n is the number of reﬂections and p is the total number of parameters reﬁned.
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Cytotoxicity was determined by the colorimetric MTT assay
(MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide) as described previously [39]. Brieﬂy, cells were harvested
by trypsinisation and seeded into 96-well plates in volumes of
100 lL/well. Depending on the cell line, different cell densities
were used to ensure exponential growth of the untreated controls
during the experiment: 1.0  103 (CH1), 2.0  103 (SW480),
3.0  103 (A549). In the ﬁrst 24 h the cells were allowed to settle
and resume exponential growth. Then the test compounds were
dissolved in DMSO, serially diluted in medium and added to the
plates in volumes of 100 lL/well so that the DMSO content did
not exceed 0.5%. After continuous exposure for 96 h (in the incuba-
tor at 37 C and under 5% CO2), the medium was replaced with
100 lL/well RPMI 1640 medium (supplemented with 10% heat-
inactivated fetal bovine serum and 4 mM L-glutamine) and MTT
solution (MTT reagent in phosphate-buffered saline, 5 mg/mL) in
a ratio of 7:1, and plates were incubated for further 4 h. Then the
medium/MTT mixture was removed and the formed formazan
product was dissolved in DMSO (150 lL/well). Optical densities
at 550 nm were measured (reference wavelength 690 nm) with a
microplate reader (BioTek ELx 808). The quantity of viable cells
was expressed as a percentage of untreated controls, and 50%
inhibitory concentrations (IC50) were calculated from the concen-
tration-effect curves by interpolation. Every test was repeated in
at least three independent experiments, each consisting of three
replicates per concentration level.3. Results and discussion
3.1. Synthesis and characterization of organic compounds and their
metal complexes
In the case of the paullones, substitution in position 9 of the li-
gand backbone led to pronounced differences both in cytotoxic and
in enzymatic inhibitory activity. Electron-withdrawing halo sub-
stituents had favourable effects on both free ligands and their me-
tal complexes [18,31]. All this prompted us to investigate the effect
of substitution in position 8 of the indoloquinoline backbone onantiproliferative activity of ruthenium- and osmium-arene com-
plexes with the ligands HL1–HL3 reported by us previously
[38,39]. Brieﬂy, the ligand backbone was assembled in a one-pot
reaction from substituted aminobenzylamine and isatin in glacial
acetic acid [27] (Scheme 1). The indoloquinolin-6-ones were fur-
ther chlorinated with POCl3. Treatment of 6-chloro-indoloquino-
lines with N2H4H2O gave rise to the indoloquinoline-6-azines.
Finally, condensation reaction of 2-acetylpyridine with the corre-
sponding azine afforded the chelating ligands HL1–HL3. For com-
parison two ligands with substituents in position 2, namely HL4
and HL5 have also been prepared and characterised (vide infra).
Complexes 1a,b3a,b (Scheme 2) were prepared from [M(g6-p-
cymene)Cl(l-Cl)]2, where M = RuII or OsII, and indoloquinolines
HL1–HL3 in absolute ethanol in 25–88% yield by exploring the
l-chlorido-bridge splitting reaction. The ESI mass spectra of the
complexes showed a single strong peak at m/z 636, 656, 702 for
the ruthenium compounds 1a–3a, andm/z 726, 746, 790 for the os-
mium congeners 1b–3b, which in all cases can be attributed to the
[MCl]+ ion.
The 1H and 13C NMR spectra are also consistent with the chem-
ical formulae proposed for 1a,b–3a,b (Scheme 2). The number of
resonances indicates C1 point symmetry for both investigated li-
gands and complexes. All complexes are racemates due to the pres-
ence of the stereogenic metal centre. They show a typical pattern
of the four diastereotopic doublets of the aromatic p-cymene pro-
tons between 6.06 and 5.30, and between 6.34 and 5.43 ppm for
the ruthenium(II) and osmium(II) complexes, respectively.
One feature of note for this class of substances is the upﬁeld
shift of the quaternary, aromatic carbon C6a to about 103 ppm in
all complexes (ca. 105 ppm for HL1–3), caused by the three sur-
rounding electron withdrawing nitrogen atoms N5, N11 and N12.
(The atom numbering scheme is depicted in Chart S1).
Most of the resonances did not shift signiﬁcantly after complex-
ation. As expected, the most noteworthy changes concern the
atoms in the close proximity to the metal centre. A downﬁeld shift
by 9–11 ppm was observed for C14 (166–168 ppm versus 156–
157 ppm in the free ligands), the shift being about 1 ppm larger
in the case of the osmium centre. C17 was shifted downﬁeld by
about 7 ppm (156 ppm versus 149 ppm), and C18–C20 showed up-
ﬁeld shifts (4–5 ppm), again with a 1 ppm greater change for the
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cant, e.g. 2–3 ppm upﬁeld shift for C6, C6a and C21. The structures
proposed for 1a,b3a,b were further conﬁrmed by X-ray
crystallography.Fig. 2. ORTEP view of the cation [OsCl(p-cymene)(HL1)]+ in 1b1.38H2O
0.25(C2H5)2O with thermal displacement parameters drawn at 30% probability
level. Selected bond distances (Å) and angles (): Os1Cl1 2.4188(14), Os1N13
2.095(5), Os1N17 2.081(5), Os1Carene(av) 2.203(9), N5C6 1.365(7), C6N12
1.313(7), N12N13 1.397(6), N13C14 1.296(7) Å; N13N12C6N5–10.6(8),
N13C14C16N17–10.3(7).3.2. X-ray crystallography
The results of the X-ray diffraction studies of HL1, HL4CH3OH,
HL52C2H5OH, [(g6-p-cymene)Os(L1)Cl]Cl1.38H2O0.25Et2O (1b
1.38H2O0.25Et2O), [(g6-p-cymene)Ru(L3)Cl]ClCH3OH (3aCH3OH),
[(g6-p-cymene)Os(L3)Cl]Cl0.75H2O (3b0.75H2O) are shown in
Fig. 1–3 and Figure S1, respectively. All three complexes crystallised
in the triclinic centrosymmetric space group P1, while the indolo-
quinoline derivatives in the monoclinic space group P21/n. The
asymmetric units of metal complexes consist of two, one and two
crystallographically independent complexes of 1b, 3a and 3b,
respectively, and-co-crystallised solvent. The complexes have a typ-
ical ‘‘three-leg piano-stool’’ geometry of ruthenium(II) and osmiu-
m(II)-arene complexes, with an g6 p-bound p-cymene ring
forming the seat and three other donor atoms (two nitrogens, N13
and N17, of indolo [3,2-c]quinoline and one chlorido ligand) as the
legs of the stool.
The conformation adopted by the indoloquinoline ligand HL1 is
very close to that of HL5 (in HL52C2H5OH), while being quite dif-
ferent from that found for HL4 (in HL4CH3OH), an isomer of HL1
with methyl group in position 2 of the molecular backbone. This
difference is clearly seen by comparing the torsion angle
HN13C14C16N17 of 3.85(17) and 4.95(19) in HL1 and HL5, respec-
tively, with that of 163.91(13) in HL4. A strong hydrogen bond-
ing interaction is evident between atom N11 acting as proton
donor and atom N17i (x + 0.5, y0.5, z + 0.5) of the neighbour-
ing molecule [N11  N17i 2.8593(15) Å, N11H  N17i 173.0] in
HL1. In HL4 the atom N11 is also involved in intermolecular H-
bonding with oxygen atom of the co-crystallised methanol mole-
cule acting as proton acceptor. The N11H  O1i(x1, y + 1, z + 1)
bond is also strong [N11  O1i 2.7491(17) Å, N11H  O1i
170.1]. The methanol molecule also acts as a proton donor in H-
bonding to atom N17ii(x + 0.5, y + 0.5, z0.5). The parameters
O1  N17ii 2.7342(18) Å, O1H  N17ii 169.2 also suggest strong
interaction. The conformation adopted by HL5 is stabilised by
intermolecular hydrogen bonding interactions with an ethanol
molecule as shown in Figure S1.
Another feature of note is the presence of isolated pairs of mol-
ecules or complex cations with offset parallel arrangement stabi-
lised by p-stacking interactions in all compounds studied byFig. 1. ORTEP view of HL1 (left) and HL4 (right) with thermal displacement parameters
N5C6 1.3718(16), C6N12 1.3201(16), N12N13 1.3874(14), N13C14 1.2913(16) Å; N
C6N12 1.3238(19), N12N13 1.3839(18), N13C14 1.2969(19) Å; N13N12C6N5–X-ray diffraction, but HL52C2H5OH. The interplanar separation
of the indoloquinoline backbones in the pairs is of 3.393,
3.483, 3.448, 3.396 and 3.744 Å in HL1, HL4CH3OH,
1b1.38H2O 0.25(C2H5)2O, 3aCH3OH and 3b0.75H2O, respectively
(see Figures S2S6). Figure S7 shows the packing diagram with
hydrogen bonding interactions of 3aCH3OH. The observed packing
peculiarities of indoloquinolines and their metal complexes
suggest, that these compounds in contrast to indolobenzazepines
possess more potential to act as DNA intercalators.3.3. Optical spectra and aqueous solution behaviour
Fig. 4 depicts the UV–Vis spectra of the free ligand HL1 and its
Ru- and Os-complex (1a and 1b, respectively) in methanol. The
free ligand exhibits strong absorptions with maxima at 229 and
265 nm due to intraligand pp⁄ transitions. Upon complexation
to Ru and Os-arene moieties a strong band at 298 and 303 nm,
respectively, appeared. In addition another absorption in the visi-
ble region with maximum between 450 and 500 nm is seen, which
can presumably be attributed to metal-to-ligand charge transfer.drawn at 50% probability level. Selected bond distances (Å) and angles () for HL1:
13N12C6N5 6.14(16), N13C14C16N17 3.85(17); for HL4: N5C6 1.369(2),
0.3(2), N13C14C16N17–163.91(13).
Fig. 3. ORTEP views of the cation [RuCl(p-cymene)(HL3)]+ in 3aCH3OH (left) and of the ﬁrst crystallographically independent cation [OsCl(p-cymene)(HL3)]+ in 3b0.75H2O
(right) with thermal displacement parameters drawn at 50% and 30% probability level, respectively. Selected bond distances (Å) and angles (): RuCl1 2.3965(7), RuN13
2.084(2), RuN17 2.089(2), RuCarene(av) 2.208(11), N5C6 1.368(3), C6N12 1.320(3), N12N13 1.409(3), N13C14 1.304(3) Å; N13N12C6N5–2.7(4),
N13C14C16N17 5.4(3); Os1Cl1 2.4049(8), Os1N13 2.097(2), Os1N17 2.072(2), RuCarene(av) 2.187(12), N5C6 1.366(4), C6N12 1.314(4), N12N13 1.398(3),
N13C14 1.303(4) Å; N13N12C6N5–14.0(4), N13C14C16N17–10.9(4).
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plexes with respect to hydrolysis was studied at 298 K over 24 h by
UV–Vis spectroscopy. The osmium complexes 1b3b are quite sta-
ble in aqueous solution with 1% DMSO, while ruthenium congeners
(1a3a) undergo hydrolysis to a certain extent (Figure S8). To fur-
ther investigate the nature of changes observed in UV–Vis spectra
the experiment was repeated by using higher concentrations of
ruthenium complex in 10% DMSO-d6 in D2O as a solvent and the
process was monitored by 1H NMR spectroscopy. There were no
signs of decomposition or release of ligands after 24 h, possibly ow-
ing to the much higher concentration of the complex in the NMR
tube (ca 2 mM compared to 35–40 lM in the UV–Vis experiment).
Partial dissociation of the ruthenium(II) complexes can be expected
(in case of not very high thermodynamic stability) with decreasing
analytical concentrations. Therefore, the aqueous behaviour was
further investigated by analytical HPLC. The results for complexes
3a and 3b are illustrated in Figure S9. Whereas the initial ruthe-
nium complex underwent at least twominor reactions, the osmium
complex 3b remained intact over 24 h, what is typical for other os-
mium(II)-arene complexes [37,46,47], which aremarkedlymore in-
ert compared to ruthenium congeners.Table 2
Comparison of cytotoxicity of ruthenium(II)- and osmium(II)-arene complexes with3.4. Cytotoxicity in cancer cells
To determine the cytotoxicity of the ruthenium(II)- and os-
mium(II)-arene complexes of indoloquinolines, a colorimetricFig. 4. UV–Vis spectra of HL1 (37 lM, green line) and its Ru- and Os complex 1a
(36 lM, blue line) and 1b (39 lM, red line) in methanol. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)microculture assay (MTT assay) was used in three human cancer
cell lines (A549, CH1, SW480), yielding IC50 values in the 107–
106 M range after continuous exposure for 96 h (Table 2). A549,
a generally more chemoresistant cell line, is the least sensitive to
all the tested compounds, whereas in CH1 and SW480 cells up to
one order of magnitude lower IC50 values were found. The uncom-
plexed ligands could not be tested because of their insufﬁcient
solubility.
Comparison of the ruthenium(II) with their osmium(II) ana-
logues shows up to ﬁve times higher activity of the former in
SW480 cells, whereas in CH1 and A549 cells all IC50 values are in
a comparable range. The different substituents, methyl (1a, 1b),
chloro (2a, 2b) or bromo (3a, 3b) in position 8, have no pronounced
(if any) effect on cytotoxicity of the complexes (Table 2, Fig. 5).
This is in accordance with structure–activity relationships of re-
lated copper(II) complexes with indoloquinolines reported previ-
ously [39], showing that major effects on cytotoxicity were only
observed for the presence/absence of a methyl group at c14 in
the ligand side chain, which is invariably methylated in all the
ruthenium(II) and osmium(II) complexes studied here. The cop-
per(II) complexes of the ligands methylated at c14 are 10–50 times
more cytotoxic in all tested cell lines. Related ruthenium(II) andmodiﬁed indoloquinoline ligands 1a,b3a,b vs. 4a,b6a,b (reported previously [38])
in three human cancer cell lines.
Compound IC50a (lM), 96 h
A549 SW480 CH1
1a 2.3 ± 0.7 0.13 ± 0.03 0.22 ± 0.03
1b 1.9 ± 0.2 0.67 ± 0.14 0.22 ± 0.01
2a 2.2 ± 0.7 0.38 ± 0.06 0.34 ± 0.09
2b 2.5 ± 0.4 0.83 ± 0.24 0.23 ± 0.04
3a 1.6 ± 0.3 0.33 ± 0.04 0.20 ± 0.05
3b 2.0 ± 0.2 0.44 ± 0.15 0.20 ± 0.03
4a 2.0 ± 0.4 0.28 ± 0.02 0.19 ± 0.02
4b 3.2 ± 0.4 0.57 ± 0.20 0.19 ± 0.08
5a 9.3 ± 3.4 5.0 ± 1.0 3.8 ± 0.6
5b 3.9 ± 0.5 1.2 ± 0.3 0.55 ± 0.14
6a 7.2 ± 1.7 1.5 ± 0.6 1.3 ± 0.2
6b 7.8 ± 2.1 2.3 ± 0.4 1.0 ± 0.4
[g6-p-cymene)Ru(II)(en)Cl](PF6)b 7.1 ± 1.1 3.5 ± 0.5 4.4 ± 0.9
a 50% Inhibitory concentrations (means ± standard deviations from at least three
independent experiments), as obtained by the MTT assay using exposure times of
96 h.
b Taken from Ref. [48].
Fig. 5. Concentration-effect curves of complexes 1a, 1b, 2a, 2b, 3a and 3b in the
human cancer cell lines A549 (A), CH1 (B), SW480 (C), all determined by the MTT
assay using continuous exposure for 96 h.
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loquinoline ligands are substituted in position 2, showed differ-
ences dependent on the substituent identity, with the methyl
derivative exhibiting the strongest activity, followed by bromo
and chloro substituted species. Halo substitution in position 8 is
more favourable for cytotoxicity than that in position 2 (up to a
factor 13 for the chloro couple 2a,b versus 5a,b and 6.5 for the bro-
mo complexes 3a,b versus 6a,b, respectively), whereas the position
of the methyl substituent has nearly no impact on cytotoxicity.
[g6-p-cymene)Ru(en)Cl](PF6), [48] taken as a well-known refer-
ence compound, is by a factor of 2 in A549, and up to a factor of
10 in CH1 and SW480 cells less cytotoxic (Table 2), while another
compound, [g6-p-cymene)Ru(azpy)Cl](PF6), where azpy = phenyl-
azopyridine, which is chemically more closely related to 1–6
shows IC50 values higher than 100 lM in A549 cells [49]. Hence,
the indoloquinoline moiety makes a major contribution to the
activity of these compounds.4. Concluding remarks
Six new ruthenium- and osmium-arene complexes bearing
modiﬁed indoloquinoline ligands were synthesized. Thecompounds were comprehensively characterised by 1D and 2D
NMR techniques, ESI mass spectrometry, optical spectroscopy
and X-ray crystallography (three ligands and three complexes).
Complexation of indoloquinoline ligands with ruthenium(II) or
osmium(II) resulted in improved solubility in biological media
enabling biological assays. Substitution in position 8 seems to be
more favourable for the cytotoxic activity than that in position 2,
at least for the halogenated indoloquinoline complexes. Especially
the most effective compounds with IC50 values in the submicrom-
olar concentration range are worth being studied for their suitabil-
ity as potential anticancer drugs.
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